All In MedTech

Device Trial Radar · NCT01210716

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

Last checked: Nov 19, 2026Latest source record: Sep 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

37

Actual

Start

Sep 2010

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
Fenwal, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 28, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
None
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.

Conditions

  • Autoimmune Diseases
  • Renal Disorders
  • Hematologic Disorders
  • Oncologic Disorders

Interventions

  • Therapeutic plasma exchangeDevice

    Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange ProcedureTime frame: After completion of the TPE procedure.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Yale University School of Medicine

    New Haven, Connecticut

  • Mayo Clinic

    Rochester, Minnesota

  • University of Virginia

    Charlottesville, Virginia

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.